News & Updates

Management of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed from androgen deprivation therapy (ADT) alone to the addition of chemotherapy and androgen receptor pathway inhibitors (ARPIs) to create more efficacious treatment regimens. At an industry-sponsored meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the Department of Urology, University of Lübeck in Germany, and Ms Helen Chan, Principal Pharmacist of the Chinese University of Hong Kong Medical Centre in Hong Kong, explored how ARPI-associated advances can further optimize outcomes, not only by improving survival, but also by maintaining health-related quality of life (HRQoL) and minimizing adverse events (AEs) and critical drug–drug interactions (DDIs).

People living with HIV-1 (PLWH) who discontinued traditional non-nucleoside reverse transcriptase inhibitor (NNRTI)- and boosted integrase strand transfer inhibitor (INSTI)-based regimens have maintained viral suppression following their switch to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF), as shown by the 144-week open-label results from the SPRINT* post-study presented at ESCMID Global 2026.

A payer-perspective study from the University of Hong Kong (HKU) indicates that single-dose baloxavir is a more cost-effective outpatient treatment option for seasonal influenza than oseltamivir, despite baloxavir’s higher acquisition cost.